Group items tagged

Almost two years after Ottawa's 'Innovation Hub' was first proposed, documents show the province has serious concerns as to whether the Hub can garner enough private-sector support or will create enough jobs to qualify for funding.

The Hub is modelled after similar centres around the world, including the MaRS Discovery District in Toronto. But the concept has local critics, including Ottawa serial entrepreneur John Ogilvie, who said governments looking to promote innovation should focus on setting up commercialization facilities at universities.

Canada has always had to fight hard to attract talent and investment

MaRS Vital to Toronto's life sciences vision is MaRS (derived from Medical and Related Sciences) a non-profit organisation and business centre located in the heart of the city. Its core function is as a biotech incubator and business park, known as MaRS Discovery District. The venture was first established in 2000 to help foster and accelerate the growth of successful Canadian businesses and, after some uncertain times, it is now gathering momentum. A separate technology transfer office, MaRS Innovation, has also been established that, it is hoped, can be a world beater in its own right (see Turning good ideas into world beaters below). The location of the MaRS building in central Toronto is important, as it is just a stone's throw away from an existing cluster of universities and academic hospitals. MaRS has many links with other research-based organisations, including collaborations with three local universities, 10 academic teaching hospitals and the Ontario Institute for Cancer Research. MaRS occupies the Old Toronto general hospital, where insulin was first discovered by Best and Banting in 1921 and then developed for use in human trials. The 21st Century organisation can build on this heritage in patient-focused discovery and development. Formerly the head of venture capital firm Primaxis, Ilse Treurnicht is chief executive of MaRS Discovery District. She acknowledges the crisis in venture capital funding, and says Canada's sector has always had less access funds through this route than other countries. This is one of the drivers behind the search for a new approach. Treurnicht says the old models of building biotech and life sciences businesses have to be discarded, as they have failed to build companies with critical mass. She says MaRS' new 'Convergence Innovation' strategy of bringing science, capital and business together will pay off.

"We call our strategy 'Convergence Innovation' and what we are trying to do is move away from the old linear model of academics struggling in their spare time to build companies or entrepreneurs doing this in a very incremental way."It takes time and it has many risk points along the way. So using this Convergence centre model to create a much more dynamic organisation which can help accelerate good ideas towards the commercialisation." But she says Canada's geography and demographics are always going to be a challenge. "This is a very large country with a small population. If you think in terms of clusters and hub regions, Canada's business hubs are separated geographically, and there is not much in between in terms of people."That means we can't try to be a little United States, because we just won't show up on the radar. We have to take a different approach. We have to think about collaboration as our potential competitive advantage - that means using networks and associations to solve problems and build businesses."So as new opportunities emerge, we can take them to market faster and hopefully with a higher success rate." The centre currently accommodates numerous start up companies, as well as those providing legal and financial services to them. AstraZeneca and GlaxoSmithKline also have offices on site. In all, MaRS provides mentoring for over 200 different companies across Ontario, and runs courses on entrepreneurship and preparing products for market.

MaRS places Israeli biotech veteran at helm

TORONTO – MaRS Innovation names Dr. Raphael Hofstein (pictured) as president and CEO. Dr. Hofstein comes to MaRS Innovation by way of Israel, where he was president and CEO of tech transfer company Hadasit Ltd.

“We are delighted to welcome Dr. Hofstein,” says Mary Jo Haddad, chair of MaRS Innovation, which is a subset of the Queen’s Park-sponsored innovation hub MaRS Discovery District.

The Ivey Centre for Health Innovation and Leadership was launched this year with a $5-million push from the Canadian government. The latest Ivey initiative has the goal of bringing students together with experts from the science and business sectors, with the ultimate goal of better identifying and commercializing health technologies.Dr. Kellie Leitch, a Hospital for Sick Children orthopedic surgeon, is the first executive director of the centre, which is based at Western.

She is sitting in the basement of MaRS, a scientific hub of activity in downtown Toronto where labs, business and major Toronto teaching hospitals are brought together under one roof.

The Ivey centre will focus on giving the educational capability to our students so they become really well educated in innovation and commercialization, so we can keep things here at home in Canada and grow those products."

Toronto’s MaRS Discovery District has combined the creative genius of science and technology with the drive of entrepreneurs and capital to create a marriage that will see more Canadian ideas commercialized in this country and for those efforts it has won the Canadian Urban Institute’s 2009 Creative City Award to be granted to MaRS on June 5 at the Urban Leadership Awards in Toronto.

“MaRS has found a creative way for science and business to collaborate rather than compete and to help Canada become a knowledge-based economy. This award recognizes them as a leader in stimulating the creative capacity of the city and advancing entrepreneurship, not only in science and technology but also in social ventures. 

Located in the Discovery District of Toronto, where billions of dollars of creative capital are created every year, the MaRS Centre first opened in 2005 in two new towers that bookend a heritage building that once housed the Toronto General Hospital. The three buildings, that total 700,000 sq. ft, house labs, companies of all sizes, business advisors and investors. Its professional services include hands-on advisory services, entrepreneurial programming and both structured and electronic networking. A second building phase of the MaRS Centre will add 750,000 sq ft and is planned to open in the next few years. “The underlining reason for creating MaRS is to capture the value of Canadian discoveries and to better commercialize these innovations at home in Canada,” said MaRS CEO Ilse Treurnicht. “Hub cities like Toronto are key drivers in shaping Canada’s innovation economy. MaRS works to strengthen the pull of that hub, acting as an accelerator and building the best ideas into companies that can compete on the world stage but are anchored here,” said Treurnicht.

MaRS aggregates the discovery pipelines of its member institutions, which include three universities, 10 academic teaching hospitals, and the Ontario Institute for Cancer Research.

MaRS is another good example. Located in the heart of downtown Toronto, the MaRS facility is less than a mile from five major teaching hospitals, the Ontario legislature, and the University of Toronto. More than two dozen research institutes and Toronto’s financial district are also nearby.

Consequently, MaRS is a vertical incubator, with a wide variety of companies and stages of development. That mix helps companies better understand the conditions that foster growth. MaRS is home to more than 65 organizations, including The Hospital for Sick Children, the Ontario Institute for Cancer Research, Merck Frosst Canada, the McEwen Centre for Regenerative Medicine, Celtic House Venture Partners, AIM Therapeutics, and AstraZeneca Canada.